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Abstract: We investigated the size-based isolation and enumeration of circulating tumor cells (CTCs)
using a centrifugal microfluidic device equipped with a fluid-assisted separation technology (FAST)
disc. We further assessed the correlations among CTCs, cancer antigen-125 (CA125) levels, and
clinical course of the disease in a prospective analysis of 47 serial blood samples collected at multiple
time-points from 13 ovarian cancer patients. CTCs were isolated from whole blood using the FAST
disc and were classified as epithelial cell adhesion molecule (EpCAM)/cytokeratin+, CD45−, and
4′,6-diamidino-2-phenylindole (DAPI)+. Mean CTC count at baseline was 20.2; 84.62% of patients
had more than one CTC at baseline and had decreased CTCs counts after surgery and chemotherapy.
The CTC counts in eight patients with complete responses were <3. CTC counts were correlated with
CA125 levels in three patients without recurrence; they were elevated in three patients with recurrence
and normal CA125 concentrations. CTC counts and CA125 levels showed high concordance with
directional changes (increasing 71.4%; non-increasing 75.0%). CTC counts showed higher associations
with clinical status, sensitivity (100.0% vs. 60.0%), positive predictive value (55.6% vs. 42.9%), and
negative predictive value (100.0% vs. 87.5%) than CA125 levels. CTC counts were better associated
with treatment response and recurrence than CA125 levels.
Keywords: circulating tumor cells; fluid-assisted separation technology; centrifugal microfluidic
device; CA125; ovarian cancer
1. Introduction
Ovarian cancer is the eighth leading cause of death due to malignancies in Korean women and
has a relatively poor prognosis compared to other gynecologic cancers [1]. Most patients are diagnosed
with late-stage disease owing to the lack of symptoms and a useful screening tool. Cancer antigen-125
(CA125) is the biomarker mainly used for initial diagnosis and treatment monitoring in ovarian
cancer [2]. CA125 concentrations >30 U/mL are generally considered to indicate recurrence in ovarian
cancer. However, CA125 levels have poor sensitivity and specificity. Moss et al. [3] reported 88.6%
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sensitivity and 72.0% specificity of CA125 levels in 799 epithelial ovarian cancer patients. Moreover,
non-malignant conditions such as endometriosis, pregnancy, and infection are well-known causes of
elevated serum CA125 levels [4]. Therefore, CA125 levels are not useful for predicting prognosis and
early recurrence after surgery and chemotherapy. Thus, identifying prognostic indicators reflecting
current disease activity is crucial for patients with ovarian cancer.
Circulating tumor cells (CTCs) are shed into the bloodstream from primary tumors, recurrences, or
metastases and possess both antigenic and genetic tumor-specific characteristics [5]. Previous studies
have demonstrated the prognostic and predictive value of CTCs in patients with breast, colorectal,
gastric, lung, and pancreatic cancers [6,7]. While the prognostic value of CTCs in ovarian cancer has
also been investigated, the results were controversial [8]. Although similar immunocytochemistry
methods were used for CTC quantification, Judson et al. reported no significant association between
CTCs and overall survival (OS) and progression-free survival (PFS) [9]. Fan et al. reported a significant
association between CTCs and PFS [10] while Pearl et al. reported significant relationships between
CTCs and both OS and PFS [11]. Optimal strategies for CTCs should be established to predict disease
activity, treatment response, or recurrence for the effective management of ovarian cancer.
Development of optimal methods for CTC enumeration in clinical settings remains a challenge
because CTCs are rarely found in the peripheral blood, and the tumor status changes continuously
with disease progression [12]. Currently, the CellSearch® system (Menarini Silicon Biosystems, Inc.,
Huntingdon Valley, PA, US), which utilizes ferrofluids loaded with an epithelial cell adhesion molecule
(EpCAM) antibody to capture CTCs [13], is the only system approved by the US Food and Drug
Administration (FDA) system for clinical use in metastatic breast, prostate, and colorectal cancers [14].
However, its clinical utility in ovarian cancer has not yet been established. Poveda et al. reported a
14.4% positivity rate for a cut-off value of two CTCs/7.5 mL and observed no significant relationship
between CTC counts and OS and PFS [15]. Behbakht et al. reported a 44.0% positivity rate for a cut-off
value of 1 CTC/7.5 mL and observed no significant association between CTC counts and PFS [16].
This pilot study of 13 patients with ovarian cancer aimed to investigate a strategy for the
enumeration and detection of CTCs based on a newly-developed centrifugal microfluidic device
equipped with a fluid-assisted separation technology (FAST) disc and to demonstrate the correlations
among CTC counts from the new device, CA125 concentrations, and clinical course of the disease.
2. Materials and Methods
2.1. Patients and Study Design
We prospectively recruited 13 women between December 2016 and August 2018. The patients
were pathologically confirmed to have primary ovarian cancer and were scheduled to undergo a
staging debulking surgery and to receive perioperative chemotherapy. They were treated at Keimyung
University Dongsan Hospital and followed up until the date of death or the last visit. Written informed
consent was obtained from all patients before enrollment. We collected 47 serial blood samples from the
13 patients at various time-points, including at diagnosis, before and after surgery or chemotherapy, and
at radiological or clinical evaluation. A staging workup was performed before recruitment according to
the 2014 International Federation of Gynecology and Obstetrics (FIGO) staging system. Information on
age at diagnosis, type of treatment including surgery and chemotherapy, date of treatment and
follow-up for evaluation, date of recurrence, initial FIGO stage, histology, response after surgery, and
chemotherapy based on Response Evaluation Criteria in Solid Tumours (RECIST version 1.1), and
serum CA125 levels was obtained from patient medical records. The study was approved by the
Institutional Review Board of Keimyung University Dongsan Hospital (IRB 2016-03-014-001) and was
conducted according to the principles of the Declaration of Helsinki.
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2.2. FAST Disc Enumeration of CTCs
We used a commercial version of the FAST disc, the CD-PRIMETM (Clinomics, Ulsan, Korea)
comprised of two parts: a CD-CTCTM Duo (disc) and a CD-OPR-1000TM (disc operating machine),
to isolate CTCs from the whole blood of ovarian cancer patients. The CD-CTCTM Duo is a label-free,
size-selective CTC isolation device that is used with the table-top-sized, stand-alone CD-OPR-1000TM
spinning system. The FAST and tangential flow filtration (TFF)-enabled CD-CTCTM Duo allowed the
rapid (>3 mL of whole blood/min) and clog-free isolation of CTCs from whole blood without any
pre-treatment steps.
Immunostaining was conducted to identify the isolated cells on the membrane in the filtration
chamber of the FAST disc. Isolated cells were fixed with 4% formaldehyde for 20 min at room
temperature and permeabilized with 0.1% Triton-X 100 for 5 min. Subsequently, washing was followed
by blocking with 10µg/mL immunoglobulin G (IgG) in phosphate-buffered saline. The cells were stained
with fluorescence-conjugated antibodies commonly used in CTC studies [17,18]: anti-cytokeratin (CK)
(CAM5.2; BD, Franklin Lakes, NJ, USA mixed with AE1/AE3; eBioscience, San Diego, CA, USA) and
anti-EpCAM (9C4; BioLegend, San Diego, CA, USA) for CTCs and anti-CD45 (H130; Life Technologies,
Carlsbad, CA, USA) for white blood cells (WBCs); 4,6-diamidino-2-phenylindole (DAPI) was used
for nuclear staining. Merged images of three different colors were used to distinguish tumor cells
from WBCs. Cells that showed CK+ or EpCAM+ (FITC channel), CD45- (PE channel), and DAPI+
(DAPI channel) and were morphologically intact were identified as CTCs while cells with high CD45
expression were identified as WBCs. The fluorescence images of isolated cells on the membrane were
automatically scanned on a Bioview workstation (BioView, Rehovot, Israel).
2.3. Cell Culture and Spike Experiment
SKOV3 and OVCAR3 ovarian cancer cell lines were purchased from the American Type
Culture Collection (Manassas, VA, USA) and cultured with Roswell Park Memorial Institute (RPMI)
medium including fetal bovine serum (FBS) (5% FBS for SKOV3 and 10% FBS for OVCAR3) and 1%
antibiotics/antimycotics at 37 ◦C under 5% CO2. For the spiking experiments, the cells were labeled with
CellTracker CMFDA (Life Technologies, Carlsbad, CA, USA) fluorescent dye before the experiment
according to the manufacturer’s protocol.
2.4. Statistical Analysis
Exploratory statistical analyses [19] were performed to assess the clinical correlation between
CTC counts and CA125 levels according to the treatment response. The treatment response was
classified as complete response (CR) or progressive disease (PD) by a computerized tomography (CT)
scan. Biomarker changes were also divided into increasing or non-increasing. Sensitivity, specificity,
positive predictive value (PPV), and negative predictive value (NPV) were calculated to assess the
concordance between the directional changes in CTC counts/CA125 levels and the treatment response.
Fisher’s exact tests were used to determine the correlation between each marker and the treatment
response. p < 0.05 was considered statistically significant. All statistical analyses were performed
using IBM SPSS Statistics for Windows, version 25.0 (IBM Corp., Armonk, NY, USA).
3. Results
3.1. High-Throughput, Efficient, Label-Free Isolation of CTCs from Whole Blood Using the FAST Disc
The FAST disc is a centrifugal microfluidic device with a track-etched polycarbonate membrane
(pore size: 8 µm) for label-free CTC isolation. The FAST disc comprised three chambers: a sample
loading chamber, a filtration chamber with a membrane, and a waste collection chamber (Figure 1A).
In the filtration chamber, the membrane is assembled in a direction parallel to the centrifugal force.
Thus, filtration through the pore occurs in a direction perpendicular to the centrifugal force, similar
to that in TFF, which minimizes clogging. Furthermore, the design allows a uniform pressure drop
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across the whole membrane into the bottom chamber (underneath the membrane) filled with liquid
(Figure 1B), which enables the isolation of intact cells with minimal pressure. A CD-OPR-1000TM was
used to operate the FAST discs. The experimental protocol was very simple. The FAST disc was loaded
into the CD-OPR-1000TM and centrifuged (Figure 1C). Both blood filtration (Figure 1D) and washing
(Figure 1E) steps were conducted using this simple operation. By using the CD-PRIMETM, 3 mL of
whole blood was processed within 1 min. Before applying the blood samples to the FAST disc, the
performance of the FAST disc was confirmed using whole blood spiked with 40–150 SKOV3 and
OVCAR3 cells. The mean capture efficiency was 87.5 ± 4.2% based on nine experiments with SKOV3
and 84.7 ± 9.1% based on seven experiments with OVCAR3 (Figure 1F).
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Figure 1. Mechanism and workflow of the CD-PRIMETM (A) image of the CD-CTCTM Duo; (B) schematic
illustration of CTC isolation in the filtration chamber; (C) image of the CD-OPR-1000TM; (D,E) separate
images of disc operation before and after washing; (F) FAST disc capture efficiency test with whole
blood spiked with SKOV3 and OVCAR3 cells. The corresponding capture efficiencies were 87.5 ± 4.2%
and 84.7 ± 9.1%, respectively (mean ± SD), respectively.
3.2. Patient Characteristics
This study enrolled a total of 13 women with ovarian cancer. Their characteristics are shown
in Table 1. The median age at diagnosis was 56 years (range 40–75 years). The histology of ovarian
cancer was high-grade, serous carcinoma in nine patients. The initial FIGO stages in four, seven, and
two patients were I–II, III, and IV, respectively. All patients underwent surgery and chemotherapy,
and 11 patients achieved CRs. Six patients had a recurrence in the lung or liver or peritoneal seeding.
The baseline CA125 concentrations were high in most patients, except for those with stage I disease;
CTCs were detected in the baseline samples of 84.62% of patients (11/13). All patients underwent
debulking surgery including total abdominal hysterectomy, bilateral salpingo-oophorectomy, bilateral
pelvic lymph node dissection, para-aortic nodal dissection, appendectomy, and omentectomy.
Thirteen patients received platinum doublet-based adjuvant chemotherapy, such as paclitaxel plus
carboplatin with or without bevacizumab for 4–6 cycles, and four patients received neoadjuvant
chemotherapy before surgery due to an unresectable status. After therapy, samples from 10 patients
were collected and tested. In 90% of patients, CA125 levels and CTC counts were lower than those at
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baseline. Only one patient (Patient 6) had increased CTC counts after therapy. This atypical patient
also had a normal CA125 concentration (<30 U/mL) at baseline.




























1 65 IIIC High-grade serous carcinoma 3186.5 76 CR 5.8 0 7
2 67 IIIC High-grade serous carcinoma 76 26 CR 8.1 0 7
3 55 IIIC High-grade serous carcinoma 4278.5 5 CR 11.3 0 5
4 53 IC Mucinous carcinoma 18.2 64 CR 8.5 1 5
5 49 IIIA2 High-grade serous carcinoma 631.9 55 CR 9.3 2 4
6 56 IC High-grade serous carcinoma 25.7 0 CR 7.7 3 4
7 75 IV Adenocarcinoma with serous carcinoma 10,000 0 PR 244.5 0 4
8 40 IIB Clear cell carcinoma 34.6 13 CR 41.6 3 3
9 59 IIB High-grade serous carcinoma 696.4 1 CR 65.1 0 3
10 46 IIIC Clear cell carcinoma 2432.8 6 CR 153.1 0 2
11 47 IV High-grade serous carcinoma 553.3 2 CR NA NA 1
12 66 IIIC High-grade serous carcinoma 3399.8 10 CR NA NA 1
13 65 IIIC High-grade serous carcinoma 8767.4 4 PR NA NA 1
FIGO, International Federation of Gynecology and Obstetrics; CTCs, Circulating Tumor Cells; CR, complete response;
PR, partial response.
From each patient sample, isolated cells were stained and discriminated based on the conventional
criteria for CTC identification: EpCAM/CK+, DAPI+, and CD45–. Figure 2 shows representative CTC
images from patient samples.
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3.3. Detection of CTCs and Their Correlation with CA125 Concentrations
At baseline, 84.62% of patients were positive for CTCs, with one or more CTCs detected in 3 mL
of blood (range 1–76). The mean and median CTC counts in all patients at baseline were 20.2 and 6.0,
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respectively. The median follow-up duration was 22.7 months (range 5.2–28.7). Most patients presented
with decreased CTC counts after surgery and chemotherapy, except for two patients with no CTCs at
baseline. At the time of CR, the CTC counts in eight patients were <3.
The correlation analysis between CTC counts and CA125 levels according to the clinical course of
the disease included patients (1) with >3 blood samples, (2) whose initial CA125 levels were higher
than normal (30 U/mL), and (3) who showed CR based on imaging findings after surgery. Based on
these criteria, six patients were selected and were divided into the no recurrence and recurrence groups.
The three patients in the no recurrence group showed similar patterns for CTC counts and CA125 levels,
which were correlated with the clinical course. Patient 1 was diagnosed with ovarian cancer, high-grade
serous carcinoma, and had an initial FIGO stage of IIIC. The pre-treatment CTC count and CA125
concentration were 76/3 mL and 3186.5 U/mL, respectively. After perioperative chemotherapy and
surgery, both parameters decreased to baseline levels, and CR was observed on computed tomography
(CT) performed at the end of chemotherapy (Figure 3A). Patient 5 was diagnosed with ovarian cancer,
high-grade serous carcinoma, and had an initial FIGO stage of IIIA2. The pre-treatment CTC count and
CA125 concentration were 55/3 mL and 631.9 U/mL, respectively. After surgery and chemotherapy,
a durable CR was observed on CT; the CTC count and CA125 concentration were 2/3 mL and 9.3
U/mL, respectively, which further decreased to 0/3 mL and 10.0 U/mL, respectively, after 14 months
(Figure 3D). Patient 8 was diagnosed with ovarian cancer, clear cell carcinoma, and had an initial FIGO
stage of IIB. The pre-treatment CTC count and CA125 concentration were 13/3 mL and 67.8 U/mL,
respectively. The changes of both parameters were similar during treatment, and a CR was observed
after two months (Figure 3E).
The three patients in the recurrence group showed similar CTC and CA125 patterns. However,
the CTC counts increased before or after recurrence while the CA125 concentrations remained in the
normal range. For example, Patient 2 was diagnosed with ovarian cancer, high-grade serous carcinoma,
and had an initial FIGO stage of IIIC. The pre-treatment CTC count and CA125 concentration were
26/3 mL and 76.0 U/mL, respectively. After chemotherapy and surgery, the corresponding values were
0/3 mL and 8.1 U/mL, respectively, and a CR was observed on CT. Recurrence was detected five months
later with the appearance of new lung nodules. An increase in the CTC count was followed by a
recurrence, although the CA125 concentration remained within the normal range (Figure 3B). Patient 3
was diagnosed with ovarian cancer, high-grade serous carcinoma, and had an initial FIGO stage of IIIC.
The pre-treatment CTC count and CA125 concentration were 5/3 mL and 4278.5 U/mL, respectively.
After surgery and chemotherapy, these values decreased to 0/3 mL and 11.3 U/mL, respectively, and
a CR was observed on CT. Five months later, an increase was observed in the CTC count, but the
CA125 level remained in the normal range; this was followed by a recurrence of peritoneal seeding
(Figure 3C). Patient 9 was diagnosed with ovarian cancer, high-grade serous carcinoma, and had an
initial FIGO stage of IIB. Twenty months after diagnosis, the CTC count increased slightly, but the
CA125 concentration remained in the normal range; a recurrence was detected in the peritoneum
(Figure 3F).
All changes in CTC counts and CA125 levels were analyzed to check for concordance and
association with the corresponding clinical assessments. First, to confirm the concordance between the
CA125 concentration and CTC count, each point of change in the six cases was classified into one of the
four categories: both increased, only CTC increase, only CA125 increase, and no change in either (no
change or decrease). The concordance in cases in which both the values increased was 71.4%. However,
the concordance in cases in which there were no increases in either value was 75.0%. According to
the directional concordance analysis, the CTC count was highly correlated with a change in CA125
concentrations (Figure 4A). To analyze the association with the corresponding clinical status, each
point of change in the six cases was classified according to recurrence. Both CA125 levels and CTC
counts had the same specificity of 77.8%. However, CTC counts showed a higher sensitivity (100.0% vs.
60.0%), PPV (55.6% vs. 42.9%), and NPV (100.0% vs. 87.5%) than CA125 concentrations. CTC counts
were significantly associated with clinical status (p = 0.003) (Figure 4B).
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were 0/3 mL and 11.3 U/mL, respectively, and a complete response was noted. Five months later, an
increase in the CTC count was noted with normal CA125 concentrations, followed by a recurrence of
peritoneal seeding; (D) Patient 5: following surgery and chemotherapy, a durable complete response
was observed on CT, with a CTC count and CA125 concentration of 2/3 mL and 9.3 U/mL, respectively,
which further decreased to 0/3 mL and 10.0 U/mL, respectively; (E) Patient 8; the patterns of CTC counts
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the CTC counts increased slightly, but the CA125 concentration remained in the normal range, and
recurrence was detected in the peritoneum.
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CTC counts/CA125 levels for increasing (sensitivity) and non-increasing (specificity) values.
4. Discussion
This pilot study successfully confirmed the performance of the FAST disc for CTC enumeration in
ovarian cancer patients. Our assessment of the clinical course over a long period demonstrated that
CTC counts showed a higher association with treatment response than CA125 levels. We observed
a >70% concordance between the changes in CTC counts and CA125 levels, and the change in CTC
counts showed higher sensitivity, PPV, and NPV than the change in CA125 levels. Pearl et al. monitored
the treatment response of six patients with >6 CTCs and with CA125 measurements and reported that
changes in CTC counts but not CA125 levels antedated changes in clinical response, from progression
to CR during and after chemotherapy and relapse [11]; this finding is consistent with those of the
present study.
The increasing number of elderly patients with ovarian cancer, which is a result of improved
life expectancy, underscores the need for optimal treatment guidelines for this population. Previously,
most elderly patients received supportive care without cancer treatment or single-modality treatments.
Because of their poor performance status and comorbidities, it is challenging to apply standard therapy to
elderly patients. However, the results of recent studies suggest that elderly patients could also benefit
from surgery and chemotherapy, with decreased perioperative mortality. Neoadjuvant chemotherapy and
less invasive cytoreductive surgery are the preferred strategies in elderly ovarian cancer patients [20,21].
Improved management of elderly patients with ovarian cancer requires careful selection of eligible patients
and the identification of useful tumor biomarkers for early diagnosis and treatment.
The importance of tumor biomarkers for improving survival in gynecological cancer patients has
been increasingly emphasized. Previous studies have tried to identify new systematic methods with
high sensitivity and specificity in gynecological cancer [22,23]. Diverse methods have been used to
develop tumor biomarkers for ovarian cancer: abnormal DNA methylation or BRCA1/BRCA2 gene
mutations through gene chip technology [24,25], serum proteomics [26], autoantibodies sequence with
immunohistochemistry [27], B7-H4 (one of the T cell costimulatory molecule B7 family) [28], and
lysophosphatidic acid [29]. In addition, some markers were shown to detect pre-invasive (p16ink4a,
p16, E-cadherin, Ki67, pRb, p53) and invasive (CEA, SCC-Ag, CD44) lesions in cervical cancer [23].
The present study sought to assess CTCs as a novel biomarker in ovarian cancer following the isolation
of CTCs with an improved device.
We developed a centrifugal microfluidic device equipped with a FAST disc. This device is based
on label-free, size-based CTC isolation without the need for sample pre-treatment and employs TFF.
This system enables clog-free, ultrafast (>3 mL/min), viabl CTC enrichment with gentle pressure
drops (~1 kPa). This device was tested in 142 patients with seven diffe nt types of canc rs, including
breast, lung, and stomach cancers [30]. The sensitivity and specificity of CTCs in gastric cance (85.3%
and 90.3%, respectively, for a cut-off of two CTCs/7.5 mL in 116 patients) [31], esophag al squamous
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cell carcinoma (85.3% and 90.0%, respectively, for a cut-off of two CTCs/7.5 mL in 116 patients) [32], and
colorectal cancer (75.0% and 100.0%, respectively, for a cut-off of five CTCs/7.5 mL in 74 patients) [33]
have been demonstrated. Moreover, Baek et al. found that patients with colorectal cancer with
≥5 CTCs showed a trend toward poor OS and PFS and frequent vascular invasion (p = 0.035) [33].
In addition, several studies comparing the FAST disc to other commercially available platforms, such
as the immunoaffinity-based CellSearch systems [34] and the AccuCyte®-CyteFinder® (Rarecyte)
selection-free system [35] have demonstrated the advantages of the FAST disc system, including its
high-throughput, label-free isolation of CTCs and high detection rate. Furthermore, this FAST disc
system used a label-free method; thus, captured CTCs can be retrieved relatively easily for downstream
analysis. This enables single-cell and genetic analysis for targeted therapy. Based on the results of
previous studies on other cancer types, we evaluated the clinical validation of this disc to enumerate
CTCs in ovarian cancer patients. The results of the present pilot study provide insightful evidence for
future studies with larger cohorts of patients with ovarian cancer.
CTCs are considered a liquid biopsy and a non-invasive method for diagnosis and prognosis.
Samples can be easily collected at multiple time-points throughout treatment, which allows real-time
monitoring of treatment response and drug resistance for all metastatic cancers [36]. Moreover,
CTC analysis enables the detection of multiple mutations within a single cell, which contributes to
an improved understanding of tumor heterogeneity and clonal evolution to establish a potential
connection between mutational status and pathway activation by combining CTC genomics and
transcriptomics [37]. However, the limitations include the lack of large-scale studies with standardized
approaches to enrich and detect CTCs [38]. Most of the studies on ovarian CTCs using the FDA-approved
CellSearch system reported negative results due to its comparatively low accuracy in CTC detection
and the limited availability of patients with ovarian cancer. In a multicenter, randomized, phase III
study including 216 ovarian cancer patients, only 14.4% were found to have two or more CTCs before
treatment using this system [15]. Liu et al. reported that CTC counts were not significantly correlated
with survival outcomes in 78 patients with ovarian cancer using this system (newly-diagnosed patients,
median time to progression [TTP] 14.0 vs. 16.5 months, p = 0.88; recurrent disease, median TTP 3.8 vs.
6.4 months, p = 0.13) [39].
Previous studies have sought to enhance CTC yield and purity based on biophysical properties
such as size, deformability, or dielectric susceptibility. By using reverse transcription-quantitative
polymerase chain reaction (RT-qPCR) to detect CTCs based on their overexpression of the cyclophilin C
gene (PPIC), Obermayr et al. showed a significantly higher presence of CTCs in the platinum-resistant
patient group than in the platinum-sensitive group, which was also related to poor prognosis in the
follow-up of 93 patients with ovarian cancer [40]. Pear et al. reported that serial measurements using
CAM+ selection of CTCs could predict therapeutic responsiveness in 31 patients with ovarian cancer
who received standard paclitaxel plus carboplatin therapy [11]. Kim et al. found that the positive
detection of postoperative CTCs using the tapered-slit filter platform was associated with inferior
PFS rates in 39 patients with stage III/IV ovarian cancer (18.8% vs. 57.1%, p = 0.077) [41]. We used
size-based isolation first to achieve high throughput, label-free, high-yield CTCs isolation and then
used the gold standard enumeration by immunostaining with EpCAM/CK+ to define CTCs.
This study has several limitations. First, the small sample size was enrolled from a single center.
Second, the numbers and timing of blood sampling were irregular; therefore, it was difficult to compare
samples from different patients to make statistically significant comparisons during the time course of
therapy. Third, we only quantified EpCAM/CK positive CTCs, although the enumeration method was
not EpCAM marker-sensitive. Fourth, we only measured the number of CTCs per sample and did not
compare our findings to those of other enumeration methods or analyze other molecular characteristics
of the CTCs. Therefore, further studies with larger sample sizes and more in-depth characterization
are required.
In conclusion, we used a FAST disc to successfully isolate sufficient CTCs from the blood of
ovarian cancer patients. We demonstrated that CTC counts were better associated with treatment
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response and recurrence throughout the clinical course than CA125 concentrations. To our knowledge,
this is the first report on the evaluation of CTCs in ovarian cancer patients using a newly-developed
centrifugal microfluidic device equipped with a FAST disc based on label-free isolation. The results
implied the potential utility of CTCs as a predictive marker for monitoring treatment response in
patients with ovarian cancer. Further large-scale prospective studies are needed to validate the FAST
disc as a diagnostic tool for personalized management of ovarian cancer.
Author Contributions: Conceptualization, Y.-K.C. and C.H.C.; methodology, Y.-K.C. and C.H.C.; formal analysis,
M.L.; investigation, M.L.; writing—original draft preparation, H.K. and M.L.; writing—review and editing, J.Y.K.,
S.-J.S., Y.-K.C., and C.H.C.; visualization, H.K.; supervision, Y.-K.C. and C.H.C. All authors have read and agreed
to the published version of the manuscript.
Funding: Work by M.L. and Y.-K.C. was supported by a grant from the Korean Health Technology R&D Project of
the Ministry of Health & Welfare, Republic of Korea (A121994) and IBS-R020-D1 funded by the Korean Government.
Acknowledgments: We thank Ji Hye Ahn, Hee Chul Park, and Kyusang Lee (Clinomics, Ulsan, Korea) for
performing the experiments to measure capture efficiency using cell line spiked blood samples shown in Figure 1F.
Conflicts of Interest: Patents on FAST-disc are licensed to Clinomics (Ulsan, Korea). Y.-K.C. receives compensation
for the sale of the FAST disc. All other authors have no conflicts of interest to declare.
References
1. Baldwin, L.A.; Huang, B.; Miller, R.W.; Tucker, T.; Goodrich, S.T.; Podzielinski, I.; DeSimone, C.P.; Ueland, F.R.;
van Nagell, J.R.; Seamon, L.G. Ten-year relative survival for epithelial ovarian cancer. Obstet. Gynecol. 2012,
120, 612–618. [CrossRef] [PubMed]
2. Rustin, G.J.; Bast, R.C., Jr.; Kelloff, G.J.; Barrett, J.C.; Carter, S.K.; Nisen, P.D.; Sigman, C.C.; Parkinson, D.R.;
Ruddon, R.W. Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer.
Clin. Cancer Res. 2004, 10, 3919–3926. [CrossRef] [PubMed]
3. Moss, E.L.; Hollingworth, J.; Reynolds, T.M. The role of CA125 in clinical practice. J. Clin. Pathol. 2005, 58,
308–312. [CrossRef] [PubMed]
4. Buamah, P. Benign conditions associated with raised serum CA-125 concentration. J. Surg. Oncol. 2000, 75,
264–265. [CrossRef]
5. Masuda, T.; Hayashi, N.; Iguchi, T.; Ito, S.; Eguchi, H.; Mimori, K. Clinical and biological significance of
circulating tumor cells in cancer. Mol. Oncol. 2016, 10, 408–417. [CrossRef]
6. van Dalum, G.; Stam, G.J.; Scholten, L.F.; Mastboom, W.J.; Vermes, I.; Tibbe, A.G.; De Groot, M.R.;
Terstappen, L.W. Importance of circulating tumor cells in newly diagnosed colorectal cancer. Int. J. Oncol.
2015, 46, 1361–1368. [CrossRef]
7. Janni, W.J.; Rack, B.; Terstappen, L.W.; Pierga, J.Y.; Taran, F.A.; Fehm, T.; Hall, C.; de Groot, M.R.; Bidard, F.C.;
Friedl, T.W.; et al. Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast
Cancer. Clin. Cancer Res. 2016, 22, 2583–2593. [CrossRef]
8. Giannopoulou, L.; Kasimir-Bauer, S.; Lianidou, E.S. Liquid biopsy in ovarian cancer: Recent advances on
circulating tumor cells and circulating tumor DNA. Clin. Chem. Lab. Med. 2018, 56, 186–197. [CrossRef]
9. Judson, P.L.; Geller, M.A.; Bliss, R.L.; Boente, M.P.; Downs, L.S., Jr.; Argenta, P.A.; Carson, L.F.
Preoperative detection of peripherally circulating cancer cells and its prognostic significance in ovarian
cancer. Gynecol. Oncol. 2003, 91, 389–394. [CrossRef]
10. Fan, T.; Zhao, Q.; Chen, J.J.; Chen, W.T.; Pearl, M.L. Clinical significance of circulating tumor cells detected
by an invasion assay in peripheral blood of patients with ovarian cancer. Gynecol. Oncol. 2009, 112, 185–191.
[CrossRef]
11. Pearl, M.L.; Dong, H.; Tulley, S.; Zhao, Q.; Golightly, M.; Zucker, S.; Chen, W.T. Treatment monitoring of
patients with epithelial ovarian cancer using invasive circulating tumor cells (iCTCs). Gynecol. Oncol. 2015,
137, 229–238. [CrossRef] [PubMed]
12. Yu, M.; Bardia, A.; Wittner, B.S.; Stott, S.L.; Smas, M.E.; Ting, D.T.; Isakoff, S.J.; Ciciliano, J.C.; Wells, M.N.;
Shah, A.M.; et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal
composition. Science 2013, 339, 580–584. [CrossRef] [PubMed]
Diagnostics 2020, 10, 249 11 of 12
13. Allard, W.J.; Matera, J.; Miller, M.C.; Repollet, M.; Connelly, M.C.; Rao, C.; Tibbe, A.G.; Uhr, J.W.;
Terstappen, L.W. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy
subjects or patients with nonmalignant diseases. Clin. Cancer Res. 2004, 10, 6897–6904. [CrossRef] [PubMed]
14. Miller, M.C.; Doyle, G.V.; Terstappen, L.W. Significance of Circulating Tumor Cells Detected by the CellSearch
System in Patients with Metastatic Breast Colorectal and Prostate Cancer. J. Oncol. 2010, 2010, 617421.
[CrossRef]
15. Poveda, A.; Kaye, S.B.; McCormack, R.; Wang, S.; Parekh, T.; Ricci, D.; Lebedinsky, C.A.; Tercero, J.C.; Zintl, P.;
Monk, B.J. Circulating tumor cells predict progression free survival and overall survival in patients with
relapsed/recurrent advanced ovarian cancer. Gynecol. Oncol. 2011, 122, 567–572. [CrossRef]
16. Behbakht, K.; Sill, M.W.; Darcy, K.M.; Rubin, S.C.; Mannel, R.S.; Waggoner, S.; Schilder, R.J.; Cai, K.Q.;
Godwin, A.K.; Alpaugh, R.K. Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating
tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal
malignancies: A Gynecologic Oncology Group study. Gynecol. Oncol. 2011, 123, 19–26. [CrossRef] [PubMed]
17. Adams, D.L.; Martin, S.S.; Alpaugh, R.K.; Charpentier, M.; Tsai, S.; Bergan, R.C.; Ogden, I.M.; Catalona, W.;
Chumsri, S.; Tang, C.M.; et al. Circulating giant macrophages as a potential biomarker of solid tumors.
Proc. Natl. Acad. Sci. USA 2014, 111, 3514–3519. [CrossRef]
18. Lampignano, R.; Yang, L.; Neumann, M.H.D.; Franken, A.; Fehm, T.; Niederacher, D.; Neubauer, H. A Novel
Workflow to Enrich and Isolate Patient-Matched EpCAM(high) and EpCAM(low/negative) CTCs Enables
the Comparative Characterization of the PIK3CA Status in Metastatic Breast Cancer. Int. J. Mol. Sci.
2017, 18, 1885. [CrossRef]
19. Pearl, M.L.; Zhao, Q.; Yang, J.; Dong, H.; Tulley, S.; Zhang, Q.; Golightly, M.; Zucker, S.; Chen, W.T.
Prognostic analysis of invasive circulating tumor cells (iCTCs) in epithelial ovarian cancer. Gynecol. Oncol.
2014, 134, 581–590. [CrossRef]
20. Vitale, S.G.; Capriglione, S.; Zito, G.; Lopez, S.; Gulino, F.A.; Di Guardo, F.; Vitagliano, A.; Noventa, M.;
La Rosa, V.L.; Sapia, F.; et al. Management of endometrial, ovarian and cervical cancer in the elderly:
Current approach to a challenging condition. Arch. Gynecol. 2019, 299, 299–315. [CrossRef]
21. Schuurman, M.; Kruitwagen, R.; Portielje, J.; Roes, E.; Lemmens, V.; Van der Aa, M. Treatment and outcome
of elderly patients with advanced stage ovarian cancer: A nationwide analysis. Gynecol. Oncol. 2018, 149,
270–274. [CrossRef] [PubMed]
22. Dong, X.; Men, X.; Zhang, W.; Lei, P. Advances in tumor markers of ovarian cancer for early diagnosis.
Indian J. Cancer 2014, 51, 72.
23. Valenti, G.; Vitale, S.G.; Tropea, A.; Biondi, A.; Laganà, A.S. Tumor markers of uterine cervical cancer: A new
scenario to guide surgical practice? Updates Surg. 2017, 69, 441–449. [CrossRef] [PubMed]
24. Peedicayil, J. The role of DNA methylation in the pathogenesis and treatment of cancer. Curr. Clin. Pharmacol.
2012, 7, 333–340. [CrossRef]
25. Jazaeri, A.A. Molecular profiles of hereditary epithelial ovarian cancers and their implications for the biology
of this disease. Mol. Oncol. 2009, 3, 151–156. [CrossRef]
26. Tessitore, A.; Gaggiano, A.; Cicciarelli, G.; Verzella, D.; Capece, D.; Fischietti, M.; Zazzeroni, F.; Alesse, E.
Serum biomarkers identification by mass spectrometry in high-mortality tumors. Int. J. Proteom.
2013, 2013, 125858. [CrossRef]
27. Tang, L.; Yang, J.; Ng, S.K.; Rodriguez, N.; Choi, P.W.; Vitonis, A.; Wang, K.; McLachlan, G.J.; Caiazzo, R.J., Jr.;
Liu, B.C.; et al. Autoantibody profiling to identify biomarkers of key pathogenic pathways in mucinous
ovarian cancer. Eur. J. Cancer 2010, 46, 170–179. [CrossRef]
28. Tringler, B.; Liu, W.; Corral, L.; Torkko, K.C.; Enomoto, T.; Davidson, S.; Lucia, M.S.; Heinz, D.E.; Papkoff, J.;
Shroyer, K.R. B7-H4 overexpression in ovarian tumors. Gynecol. Oncol. 2006, 100, 44–52. [CrossRef]
29. Wang, P.; Wu, X.; Chen, W.; Liu, J.; Wang, X. The lysophosphatidic acid (LPA) receptors their expression and
significance in epithelial ovarian neoplasms. Gynecol. Oncol. 2007, 104, 714–720. [CrossRef]
30. Kim, T.H.; Lim, M.; Park, J.; Oh, J.M.; Kim, H.; Jeong, H.; Lee, S.J.; Park, H.C.; Jung, S.; Kim, B.C.; et al.
FAST: Size-Selective, Clog-Free Isolation of Rare Cancer Cells from Whole Blood at a Liquid-Liquid Interface.
Anal. Chem. 2017, 89, 1155–1162. [CrossRef]
31. Kang, H.M.; Kim, G.H.; Jeon, H.K.; Kim, D.H.; Jeon, T.Y.; Park, D.Y.; Jeong, H.; Chun, W.J.; Kim, M.H.;
Park, J.; et al. Circulating tumor cells detected by lab-on-a-disc: Role in early diagnosis of gastric cancer.
PLoS ONE 2017, 12, e0180251. [CrossRef] [PubMed]
Diagnostics 2020, 10, 249 12 of 12
32. Choi, M.K.; Kim, G.H.; I, H.; Park, S.J.; Lee, M.W.; Lee, B.E.; Park, D.Y.; Cho, Y.K. Circulating tumor
cells detected using fluid-assisted separation technique in esophageal squamous cell carcinoma.
J. Gastroenterol. Hepatol. 2019, 34, 552–560. [CrossRef] [PubMed]
33. Baek, D.H.; Kim, G.H.; Song, G.A.; Han, I.S.; Park, E.Y.; Kim, H.S.; Jo, H.J.; Ko, S.H.; Park, D.Y.;
Cho, Y.K. Clinical Potential of Circulating Tumor Cells in Colorectal Cancer: A Prospective Study.
Clin. Transl. Gastroenterol. 2019, 10, e00055. [CrossRef] [PubMed]
34. Lim, M.; Park, J.; Lowe, A.C.; Jeong, H.-O.; Lee, S.; Park, H.C.; Lee, K.; Kim, G.H.; Kim, M.-H.; Cho, Y.-K.
A lab-on-a-disc platform enables serial monitoring of individual CTCs associated with tumor progression
during EGFR-targeted therapy for patients with NSCLC. Theranostics 2020, 10, 5181–5194. [CrossRef]
35. Dong, L.; Zhang, Z.; Smith, K.; Kuczler, M.; Reyes, D.; Amend, S.R.; Cho, Y.K.; Xue, W.; Pienta, K.J.
The combination of size-based separation and selection-free technology provides higher circulating tumor
cells detection sensitivity than either method alone in patients with metastatic prostate cancer. BJU Int. 2020.
[CrossRef]
36. Cheng, X.; Zhang, L.; Chen, Y.; Qing, C. Circulating cell-free DNA and circulating tumor cells, the “liquid
biopsies” in ovarian cancer. J. Ovarian Res. 2017, 10, 75. [CrossRef]
37. Brouwer, A.; De Laere, B.; Peeters, D.; Peeters, M.; Salgado, R.; Dirix, L.; Van Laere, S. Evaluation and
consequences of heterogeneity in the circulating tumor cell compartment. Oncotarget 2016, 7, 48625–48643.
[CrossRef]
38. Van Berckelaer, C.; Brouwers, A.J.; Peeters, D.J.; Tjalma, W.; Trinh, X.B.; van Dam, P.A. Current and future role
of circulating tumor cells in patients with epithelial ovarian cancer. Eur. J. Surg. Oncol. 2016, 42, 1772–1779.
[CrossRef]
39. Liu, J.F.; Kindelberger, D.; Doyle, C.; Lowe, A.; Barry, W.T.; Matulonis, U.A. Predictive value of circulating
tumor cells (CTCs) in newly-diagnosed and recurrent ovarian cancer patients. Gynecol. Oncol. 2013, 131,
352–356. [CrossRef]
40. Obermayr, E.; Castillo-Tong, D.C.; Pils, D.; Speiser, P.; Braicu, I.; Van Gorp, T.; Mahner, S.; Sehouli, J.;
Vergote, I.; Zeillinger, R. Molecular characterization of circulating tumor cells in patients with ovarian cancer
improves their prognostic significance—A study of the OVCAD consortium. Gynecol. Oncol. 2013, 128,
15–21. [CrossRef]
41. Kim, M.; Suh, D.H.; Choi, J.Y.; Bu, J.; Kang, Y.T.; Kim, K.; No, J.H.; Kim, Y.B.; Cho, Y.H. Post-debulking
circulating tumor cell as a poor prognostic marker in advanced stage ovarian cancer: A prospective
observational study. Medicine 2019, 98, e15354. [CrossRef] [PubMed]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
